Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration and approved the company's esketamine hydrochloride injection for sale.
Esketamine hydrochloride is a chiral cyclohexanone derivative with analgesic effects and anesthesia induced by increasing doses. It mainly exerts analgesic effects by blocking N-methyl-D-aspartate (NMDA) receptors. Used in combination with sleeping pills to induce and implement general anesthesia as a supplement to local anesthesia, child anesthesia, and for anesthesia and analgesia in emergency care.
Hengrui Pharmaceutical Esketamine Hydrochloride Injection was submitted to the State Drug Administration for registration in November 2017. It was included in the priority review by the State Drug Administration in June this year. It is the first domestic company to be approved for marketing, leading the original research drug. Fill in the domestic blank in this field.